ES2742224T3 - Anticuerpos biespecíficos anti-WT1/HLA - Google Patents
Anticuerpos biespecíficos anti-WT1/HLA Download PDFInfo
- Publication number
- ES2742224T3 ES2742224T3 ES14803300T ES14803300T ES2742224T3 ES 2742224 T3 ES2742224 T3 ES 2742224T3 ES 14803300 T ES14803300 T ES 14803300T ES 14803300 T ES14803300 T ES 14803300T ES 2742224 T3 ES2742224 T3 ES 2742224T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- set forth
- acid sequence
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCCCC*(*)(CCS*C(*)*)OOOC(CC1)C[C@@]1C1(C*)*C1 Chemical compound CCCCCCC*(*)(CCS*C(*)*)OOOC(CC1)C[C@@]1C1(C*)*C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901310P | 2013-11-07 | 2013-11-07 | |
| US201462037875P | 2014-08-15 | 2014-08-15 | |
| PCT/US2014/064621 WO2015070061A1 (en) | 2013-11-07 | 2014-11-07 | Anti-wt1/hla bi-specific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2742224T3 true ES2742224T3 (es) | 2020-02-13 |
Family
ID=51987482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14803300T Active ES2742224T3 (es) | 2013-11-07 | 2014-11-07 | Anticuerpos biespecíficos anti-WT1/HLA |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3066130B1 (https=) |
| JP (1) | JP6553069B2 (https=) |
| CN (1) | CN106414500B (https=) |
| ES (1) | ES2742224T3 (https=) |
| WO (1) | WO2015070061A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| HK1258444A1 (zh) * | 2015-10-09 | 2019-11-15 | Immatics Biotechnologies Gmbh | 抗wt1/hla特异性抗体 |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| CN109069627A (zh) * | 2016-01-14 | 2018-12-21 | 纪念斯隆-凯特琳癌症中心 | 对foxp3衍生肽特异性的t细胞受体样抗体 |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| US12178830B2 (en) | 2017-06-30 | 2024-12-31 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CN112041432A (zh) | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JP2021526365A (ja) * | 2018-05-18 | 2021-10-07 | チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 改善された標的化ｔ細胞療法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| WO2021202908A1 (en) * | 2020-04-02 | 2021-10-07 | The Board Of Regents Of The University Of Texas System | Cd5l-binding antibodies and uses for the same |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| KR20230074146A (ko) * | 2020-09-24 | 2023-05-26 | 에프. 호프만-라 로슈 아게 | T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2023180346A1 (en) * | 2022-03-22 | 2023-09-28 | Morphosys Ag | Deimmunized antibodies specific for cd3 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| MXPA06004035A (es) * | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| RU2008129827A (ru) * | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| MX2013011363A (es) * | 2011-04-01 | 2014-04-25 | Sloan Kettering Inst Cancer | Anticuerpos para peptidos citosolicos. |
-
2014
- 2014-11-07 EP EP14803300.4A patent/EP3066130B1/en active Active
- 2014-11-07 ES ES14803300T patent/ES2742224T3/es active Active
- 2014-11-07 CN CN201480061156.9A patent/CN106414500B/zh not_active Expired - Fee Related
- 2014-11-07 WO PCT/US2014/064621 patent/WO2015070061A1/en not_active Ceased
- 2014-11-07 JP JP2016553248A patent/JP6553069B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6553069B2 (ja) | 2019-07-31 |
| JP2017500057A (ja) | 2017-01-05 |
| CN106414500B (zh) | 2020-04-10 |
| CN106414500A (zh) | 2017-02-15 |
| EP3066130B1 (en) | 2019-05-15 |
| WO2015070061A1 (en) | 2015-05-14 |
| EP3066130A1 (en) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2742224T3 (es) | Anticuerpos biespecíficos anti-WT1/HLA | |
| ES2809455T3 (es) | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 | |
| ES2914177T3 (es) | Anticuerpos anti-OX40 humanizados y usos de los mismos | |
| US10239952B2 (en) | Anti-WT1/HLA bi-specific antibody | |
| ES2955074T3 (es) | Proteínas que se unen a HER2, NKG2D Y CD16 | |
| ES2935120T3 (es) | Anticuerpos anti-PSMA, moléculas de unión a antígeno biespecíficas que se unen a PSMA y a CD3, y sus usos | |
| ES2845924T3 (es) | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos | |
| US11091546B2 (en) | Optimized PNE-based chimeric receptor T cell switches and uses thereof | |
| ES2948807T3 (es) | Anticuerpos anti CD3, moléculas de unión a antígeno biespecíficas que se unen a CD3 y a CD20 y usos de los mismos | |
| ES2978993T3 (es) | Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2 | |
| US12491244B2 (en) | Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cell | |
| ES2784131T3 (es) | Polipéptidos de unión beta del receptor PDGF | |
| KR20210013160A (ko) | 다중-특이적 결합 단백질 및 그에 대한 개선 | |
| ES2717308T3 (es) | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos | |
| CN109843325A (zh) | Cd3结合抗体 | |
| US10934331B2 (en) | Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells | |
| ES2800674T3 (es) | Polipéptidos biespecíficos de unión a antígeno | |
| US20250388687A1 (en) | Epo receptor agonists and antagonists | |
| AU2014346648A1 (en) | Fc-enhanced anti-WT1/HLA antibody | |
| KR20220150274A (ko) | Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법 | |
| EP4545562A1 (en) | Fusion protein comprising anti-cd73 antibody and il-2, and use thereof | |
| HK1227903A1 (en) | Anti-wt1/hla bi-specific antibody | |
| HK1227903B (en) | Anti-wt1/hla bi-specific antibody | |
| Akkapeddi | Antibody based therapy for T-cell acute lymphoblastic leukemia: targeting IL-7 receptor | |
| CA3191224A1 (en) | Multispecific binding compounds that bind to pd-l1 |